CBD-infused coffee is growing in popularity



On Friday, the FDA will hold the first public hearing on a plan to legalize CBD in food and drinks. CBD comes from plants in the cannabis family, but unlike …

23 Comments

  1. So it’s illegal for common folk to grow unless you have a contact with the United States corporation it’s legal hmmm 🤔 these citizens are truly brainwashed. Oh I have a great idea 💡 let’s sell them water that the creator gave them freely and put it in plastic so that it will destroy their environment dummy’s

  2. Coffee is known as an antioxidation liquid, while CBD is the best medical harmonizer for humans (and pets) health. That's why there is no wonder about this winning combination. We suggest adding to the coffee also CBD- creamer for the perfect experience. Over ToBeAsYouAre (www.2bsur.net) you can have them both as free samples to test before you make any buy.

  3. Hopefully mental health facilities will become less burdened, school shootings and other acts of violence will diminish, children won't lose their parents to dementia and big pharma will find it's proper place in society. https://www.ncbi.nlm.nih.gov/pubmed/28588483
    Front Pharmacol. 2017 May 23;8:269. doi: 10.3389/fphar.2017.00269. eCollection 2017
    Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders.  Campos AC1, Fogaça MV1, Scarante FF1, Joca SRL2, Sales AJ2, Gomes FV3, Sonego AB1, Rodrigues NS1, Galve-Roperh I4,5, Guimarães FS1.

    Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes. For example, CBD attenuates the decrease in hippocampal neurogenesis and dendrite spines density induced by chronic stress and prevents microglia activation and the decrease in the number of parvalbumin-positive GABA neurons in a pharmacological model of schizophrenia.

    More recently, it was found that CBD modulates cell fate regulatory pathways such as autophagy and others critical pathways for neuronal survival in neurodegenerative experimental models, suggesting the potential benefit of CBD treatment for psychiatric/cognitive symptoms associated with neurodegeneration. These changes and their possible association with CBD beneficial effects in psychiatric disorders are reviewed here.

    https://www.ncbi.nlm.nih.gov/pubmed/28217094

    Front Pharmacol. 2017 Feb 3;8:20. doi: 10.3389/fphar.2017.00020. ECollection 2017            

    In Vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.  Watt G1, Karl T2

    Alzheimer's disease (AD) is a debilitating neurodegenerative disease that is affecting an increasing number of people. It is characterized by the accumulation of amyloid-β and tau hyperphosphorylation as well as neuroinflammation and oxidative stress. Current AD treatments do not stop or reverse the disease progression, highlighting the need for new, more effective therapeutics. Cannabidiol (CBD) is a non-psychoactive phytocannabinoid that has demonstrated neuroprotective, anti-inflammatory and antioxidant properties in vitro. Thus, it is investigated as a potential multifunctional treatment option for AD. Here, we summarize the current status quo of in vivo effects of CBD in established pharmacological and transgenic animal models for AD.

    The studies demonstrate the ability of CBD to reduce reactive gliosis and the neuroinflammatory response as well as to promote neurogenesis. Importantly, CBD also reverses and prevents the development of cognitive deficits in AD rodent models. Interestingly, combination therapies of CBD and Δ9-tetrahydrocannabinol (THC), the main active ingredient of cannabis sativa, show that CBD can antagonize the psychoactive effects associated with THC and possibly mediate greater therapeutic benefits than either phytocannabinoid alone. The studies provide "proof of principle" that CBD and possibly CBD-THC combinations are valid candidates for novel AD therapies. Further investigations should address the long-term potential of CBD and evaluate mechanisms involved in the therapeutic effects described.

Leave a Reply

Your email address will not be published.


*